These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22892214)

  • 1. Riluzole prodrugs for melanoma and ALS: design, synthesis, and in vitro metabolic profiling.
    McDonnell ME; Vera MD; Blass BE; Pelletier JC; King RC; Fernandez-Metzler C; Smith GR; Wrobel J; Chen S; Wall BA; Reitz AB
    Bioorg Med Chem; 2012 Sep; 20(18):5642-8. PubMed ID: 22892214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptide Prodrugs of the Glutamate Modulator Riluzole.
    Pelletier JC; Chen S; Bian H; Shah R; Smith GR; Wrobel JE; Reitz AB
    ACS Med Chem Lett; 2018 Jul; 9(7):752-756. PubMed ID: 30034613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Riluzole metabolism and CYP1A1/2 polymorphisms in patients with ALS.
    Ajroud-Driss S; Saeed M; Khan H; Siddique N; Hung WY; Sufit R; Heller S; Armstrong J; Casey P; Siddique T; Lukas TJ
    Amyotroph Lateral Scler; 2007 Oct; 8(5):305-9. PubMed ID: 17852022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis.
    van Kan HJ; Groeneveld GJ; Kalmijn S; Spieksma M; van den Berg LH; Guchelaar HJ
    Br J Clin Pharmacol; 2005 Mar; 59(3):310-3. PubMed ID: 15752377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1
    Shah R; Singh SJ; Eddy K; Filipp FV; Chen S
    Cancer Res; 2019 Apr; 79(8):1799-1809. PubMed ID: 30987979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
    Lee HJ; Wall BA; Wangari-Talbot J; Shin SS; Rosenberg S; Chan JL; Namkoong J; Goydos JS; Chen S
    Clin Cancer Res; 2011 Nov; 17(22):7080-92. PubMed ID: 21844014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verapamil and riluzole cocktail liposomes overcome pharmacoresistance by inhibiting P-glycoprotein in brain endothelial and astrocyte cells: A potent approach to treat amyotrophic lateral sclerosis.
    Yang T; Ferrill L; Gallant L; McGillicuddy S; Fernandes T; Schields N; Bai S
    Eur J Pharm Sci; 2018 Jul; 120():30-39. PubMed ID: 29704642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo.
    Khan AJ; Wall B; Ahlawat S; Green C; Schiff D; Mehnert JM; Goydos JS; Chen S; Haffty BG
    Clin Cancer Res; 2011 Apr; 17(7):1807-14. PubMed ID: 21325066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells.
    Wall BA; Wangari-Talbot J; Shin SS; Schiff D; Sierra J; Yu LJ; Khan A; Haffty B; Goydos JS; Chen S
    Pigment Cell Melanoma Res; 2014 Mar; 27(2):263-74. PubMed ID: 24330389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells.
    Le MN; Chan JL; Rosenberg SA; Nabatian AS; Merrigan KT; Cohen-Solal KA; Goydos JS
    J Invest Dermatol; 2010 Sep; 130(9):2240-9. PubMed ID: 20505744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1.
    Speyer CL; Nassar MA; Hachem AH; Bukhsh MA; Jafry WS; Khansa RM; Gorski DH
    Breast Cancer Res Treat; 2016 Jun; 157(2):217-228. PubMed ID: 27146584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?
    Bellingham MC
    CNS Neurosci Ther; 2011 Feb; 17(1):4-31. PubMed ID: 20236142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Riluzole, neuroprotection and amyotrophic lateral sclerosis.
    Cheah BC; Vucic S; Krishnan AV; Kiernan MC
    Curr Med Chem; 2010; 17(18):1942-199. PubMed ID: 20377511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anti-ALS drug riluzole attenuates pericyte loss in the diabetic retinopathy of streptozotocin-treated mice.
    Choi JA; Chung YR; Byun HR; Park H; Koh JY; Yoon YH
    Toxicol Appl Pharmacol; 2017 Jan; 315():80-89. PubMed ID: 27939241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Protein Kinase CK1δ with Riluzole: Could It Be One of the Possible Missing Bricks to Interpret Its Effect in the Treatment of ALS from a Molecular Point of View?
    Bissaro M; Federico S; Salmaso V; Sturlese M; Spalluto G; Moro S
    ChemMedChem; 2018 Dec; 13(24):2601-2605. PubMed ID: 30359484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Riluzole: a new agent for amyotrophic lateral sclerosis.
    Wagner ML; Landis BE
    Ann Pharmacother; 1997 Jun; 31(6):738-44. PubMed ID: 9184716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma.
    Yip D; Le MN; Chan JL; Lee JH; Mehnert JA; Yudd A; Kempf J; Shih WJ; Chen S; Goydos JS
    Clin Cancer Res; 2009 Jun; 15(11):3896-902. PubMed ID: 19458050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Liver Injury Risk Factors in Amyotrophic Lateral Sclerosis Patients Treated with Riluzole].
    Kawano C; Isozaki Y; Nakagawa A; Hirayama T; Nishiyama K; Kuroyama M
    Yakugaku Zasshi; 2020; 140(7):923-928. PubMed ID: 32612057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis.
    Gurney ME; Fleck TJ; Himes CS; Hall ED
    Neurology; 1998 Jan; 50(1):62-6. PubMed ID: 9443458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Riluzole for the treatment of amyotrophic lateral sclerosis.
    Saitoh Y; Takahashi Y
    Neurodegener Dis Manag; 2020 Dec; 10(6):343-355. PubMed ID: 32847483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.